BXTA becomes global distribution partner for new online prostate MRI self-learning tool, MRI PRO.

BXTA is pleased to announce a global agreement with MRI PRO that will see us distribute this new, online self-learning tool for prostate MRI diagnostics, designed and developed by a team of specialist MRI radiologists and urologists.

With high-level evidence (1, 2, 3, 4) now confirming prostate MRI’s place in the diagnostic process of prostate cancer detection internationally, demand for healthcare professionals experienced in interpreting and accurate reporting of MRI scans is skyrocketing. Gaining the experience that is required for accurate interpretation of prostate MRI is essential, but is difficult to obtain without the availability of immediate histological feedback. MRI PRO addresses this global need.

Saheed Rashid, Managing Director, BXTA, comments: “Prostate MRI represents the next stage in prostate cancer diagnosis, but there is an unmet demand for education and training in MRI imaging and interpretation by all healthcare professionals, including in nursing, junior doctor, urologist and radiologist training. BXTA is therefore proud to be the global distribution partner for this online learning platform that is paving the way for MRI education.”

MRI PRO is a subscription-based e-learning platform that allows healthcare professionals to test themselves on 300 of the highest quality histology-verified prostate MRI cases. All cases on MRI PRO are acquired and reported to PIRADS v.2 specifications, using 3T magnets and expert prostate MRI radiologists and experts. Users submit their answers on PIRADS score, location of index lesions and staging information for each case, and get instant feedback on how they did, including access to the actual biopsy report. The platform provides users with performance over time, with a percentage score of correct answers for the last 20 and 50 cases reviewed.

MRI PRO is also accredited by the European Accreditation Council for Continuing Medical Education (EACCME), the American Medical Association (AMA), the Royal Australasian College of Surgeons, and the Royal Australian and New Zealand College of Radiologists to earn CME points.

Associate Professor Jeremy Grummet of  MRI PRO, adds: “As an organisation, we are committed to improve the safety, precision, and efficiency of prostate cancer biopsy, and recognise the hugely important role MRI diagnostics can play. These are values which are also closely mirrored by the team at BXTA; their approach to training whole prostate cancer teams in the PrecisionPoint biopsy device is one we welcome, and are keen to mirror. We are pleased to partner with BXTA with the aim of improving the overall patient experience and delivering the best possible health outcomes.”

1  https://prostatecanceruk.org/about-us/projects-and-policies/mpmri

2  https://www.nice.org.uk/guidance/ng131/chapter/Recommendations

3  https://uroweb.org/guideline/prostate-cancer/

4  https://www.auanet.org/guidelines/mri-of-the-prostate-sop

​